Isovaleric Acidemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major isovaleric acidemia markets are expected to exhibit a CAGR of 4.39% during 2024-2034.
The isovaleric acidemia market has been comprehensively analyzed in IMARC's new report titled "Isovaleric Acidemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Isovaleric acidemia (IVA) refers to a rare inherited metabolic disorder characterized by the body's incapability to properly break down the amino acid leucine. This results in the buildup of isovaleric acid and its derivatives in tissues and bodily fluids. The disorder occurs due to a deficiency of the enzyme isovaleryl-CoA dehydrogenase, which is essential for the breakdown of leucine. The symptoms of the ailment typically appear in infancy or early childhood and can differ from mild to severe. These indications may include poor feeding, vomiting, a distinctive sweaty foot odor, lethargy, developmental delays, muscle weakness, and even life-threatening metabolic crises, which can lead to coma, epilepsy, and death if not promptly treated. The diagnosis of IVA often involves genetic testing to identify the variations in the genes causing the disorder. A healthcare professional might also perform confirmatory tests, including analyzing urine and blood for increased concentrations of isovaleric acid and its derivatives.
The increasing cases of genetic mutations, leading to the deficiency of the isovaleryl-CoA dehydrogenase enzyme are primarily driving the isovaleric acidemia market. In addition to this, the inflating utilization of effective treatments, such as dietary management to limit the intake of certain amino acids and the administration of carnitine to facilitate the excretion of toxic metabolites, is also creating a positive outlook for the market. Moreover, the widespread adoption of newborn screening programs, enabling early detection and intervention, is further bolstering the market growth. These programs aid in identifying patients shortly after birth, allowing for timely implementation of therapeutic strategies and minimizing potential complications. Apart from this, the rising usage of supportive therapies like physical therapy and speech therapy, aimed at enhancing motor skills, communication, and overall quality of life for individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of liver transplant procedures, which can offer a more permanent solution for severe cases of IVA, is also augmenting the market growth. Furthermore, the escalating demand for gene therapy, since it involves introducing functional genetic material to correct the underlying genetic mutations responsible for the disorder, is expected to drive the isovaleric acidemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the isovaleric acidemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for isovaleric acidemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the isovaleric acidemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the isovaleric acidemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the isovaleric acidemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current isovaleric acidemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the isovaleric acidemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the isovaleric acidemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the isovaleric acidemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of isovaleric acidemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of isovaleric acidemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of isovaleric acidemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with isovaleric acidemia across the seven major markets?
What is the size of the isovaleric acidemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of isovaleric acidemia?
What will be the growth rate of patients across the seven major markets?
Isovaleric Acidemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for isovaleric acidemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the isovaleric acidemia market?
What are the key regulatory events related to the isovaleric acidemia market?
What is the structure of clinical trial landscape by status related to the isovaleric acidemia market?
What is the structure of clinical trial landscape by phase related to the isovaleric acidemia market?
What is the structure of clinical trial landscape by route of administration related to the isovaleric acidemia market?
The isovaleric acidemia market has been comprehensively analyzed in IMARC's new report titled "Isovaleric Acidemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Isovaleric acidemia (IVA) refers to a rare inherited metabolic disorder characterized by the body's incapability to properly break down the amino acid leucine. This results in the buildup of isovaleric acid and its derivatives in tissues and bodily fluids. The disorder occurs due to a deficiency of the enzyme isovaleryl-CoA dehydrogenase, which is essential for the breakdown of leucine. The symptoms of the ailment typically appear in infancy or early childhood and can differ from mild to severe. These indications may include poor feeding, vomiting, a distinctive sweaty foot odor, lethargy, developmental delays, muscle weakness, and even life-threatening metabolic crises, which can lead to coma, epilepsy, and death if not promptly treated. The diagnosis of IVA often involves genetic testing to identify the variations in the genes causing the disorder. A healthcare professional might also perform confirmatory tests, including analyzing urine and blood for increased concentrations of isovaleric acid and its derivatives.
The increasing cases of genetic mutations, leading to the deficiency of the isovaleryl-CoA dehydrogenase enzyme are primarily driving the isovaleric acidemia market. In addition to this, the inflating utilization of effective treatments, such as dietary management to limit the intake of certain amino acids and the administration of carnitine to facilitate the excretion of toxic metabolites, is also creating a positive outlook for the market. Moreover, the widespread adoption of newborn screening programs, enabling early detection and intervention, is further bolstering the market growth. These programs aid in identifying patients shortly after birth, allowing for timely implementation of therapeutic strategies and minimizing potential complications. Apart from this, the rising usage of supportive therapies like physical therapy and speech therapy, aimed at enhancing motor skills, communication, and overall quality of life for individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of liver transplant procedures, which can offer a more permanent solution for severe cases of IVA, is also augmenting the market growth. Furthermore, the escalating demand for gene therapy, since it involves introducing functional genetic material to correct the underlying genetic mutations responsible for the disorder, is expected to drive the isovaleric acidemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the isovaleric acidemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for isovaleric acidemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the isovaleric acidemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the isovaleric acidemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the isovaleric acidemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current isovaleric acidemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the isovaleric acidemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the isovaleric acidemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the isovaleric acidemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of isovaleric acidemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of isovaleric acidemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of isovaleric acidemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with isovaleric acidemia across the seven major markets?
What is the size of the isovaleric acidemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of isovaleric acidemia?
What will be the growth rate of patients across the seven major markets?
Isovaleric Acidemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for isovaleric acidemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the isovaleric acidemia market?
What are the key regulatory events related to the isovaleric acidemia market?
What is the structure of clinical trial landscape by status related to the isovaleric acidemia market?
What is the structure of clinical trial landscape by phase related to the isovaleric acidemia market?
What is the structure of clinical trial landscape by route of administration related to the isovaleric acidemia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ISOVALERIC ACIDEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ISOVALERIC ACIDEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ISOVALERIC ACIDEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ISOVALERIC ACIDEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ISOVALERIC ACIDEMIA - UNMET NEEDS
10 ISOVALERIC ACIDEMIA - KEY ENDPOINTS OF TREATMENT
11 ISOVALERIC ACIDEMIA - MARKETED PRODUCTS
11.1 List of Isovaleric Acidemia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ISOVALERIC ACIDEMIA - PIPELINE DRUGS
12.1 List of Isovaleric Acidemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ISOVALERIC ACIDEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ISOVALERIC ACIDEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ISOVALERIC ACIDEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Isovaleric Acidemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Isovaleric Acidemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Isovaleric Acidemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Isovaleric Acidemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Isovaleric Acidemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Isovaleric Acidemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Isovaleric Acidemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Isovaleric Acidemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Isovaleric Acidemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Isovaleric Acidemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Isovaleric Acidemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Isovaleric Acidemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Isovaleric Acidemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Isovaleric Acidemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Isovaleric Acidemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Isovaleric Acidemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Isovaleric Acidemia - Access and Reimbursement Overview
16 ISOVALERIC ACIDEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ISOVALERIC ACIDEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ISOVALERIC ACIDEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ISOVALERIC ACIDEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ISOVALERIC ACIDEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ISOVALERIC ACIDEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ISOVALERIC ACIDEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ISOVALERIC ACIDEMIA - UNMET NEEDS
10 ISOVALERIC ACIDEMIA - KEY ENDPOINTS OF TREATMENT
11 ISOVALERIC ACIDEMIA - MARKETED PRODUCTS
11.1 List of Isovaleric Acidemia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ISOVALERIC ACIDEMIA - PIPELINE DRUGS
12.1 List of Isovaleric Acidemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ISOVALERIC ACIDEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ISOVALERIC ACIDEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ISOVALERIC ACIDEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Isovaleric Acidemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Isovaleric Acidemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Isovaleric Acidemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Isovaleric Acidemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Isovaleric Acidemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Isovaleric Acidemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Isovaleric Acidemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Isovaleric Acidemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Isovaleric Acidemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Isovaleric Acidemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Isovaleric Acidemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Isovaleric Acidemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Isovaleric Acidemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Isovaleric Acidemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Isovaleric Acidemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Isovaleric Acidemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Isovaleric Acidemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Isovaleric Acidemia - Access and Reimbursement Overview
16 ISOVALERIC ACIDEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ISOVALERIC ACIDEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ISOVALERIC ACIDEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
